Cancer Patient Tissueoid with Self-Homing Nano-Targeting of Metabolic Inhibitor

Area of Science:

• Oncology
• Biomedical Engineering
• Nanotechnology

Background:

• Current cancer medicine increasingly utilizes patient-specific treatments and advanced drug screening models.
• Living cancer tissues offer unique microenvironmental signatures, while cancer cell-derived nanovesicles (CaNVs) enable self-homing nano-targeting.

Purpose of the Study:

• To develop a novel ovarian cancer (OC) tissueoid model for drug screening.
• To create and utilize CaNVs for targeted drug delivery.
• To validate drug responses across clinical, tissueoid, and animal models for precision medicine.

Main Methods:

• Culturing OC patient tissues in a 3D gel chip to create tissueoids with perfusion for viability.
• Xenografting OC tissueoids into nude mice to model systemic cancer responses.
• Producing CaNVs loaded with chemotherapeutics or novel drugs targeting BRCA mutations or energy metabolism.

Main Results:

• Cross-validation of drug responses between OC clinical data, the tissueoid model, and the animal model.
• Demonstrated alignment in drug type-specific efficiency and BRCA mutation-dependent drug efficacy.
• Confirmed metabolism inhibition-based anti-cancer effects in the developed models.

Conclusions:

• The developed OC tissueoid model and CaNV system provide a foundation for accelerating patient-specific drug discovery.
• This approach supports the application of CaNVs for future precision medicine in ovarian cancer.
• The study highlights the potential of integrating tissueoid and nanovesicle technology for personalized cancer therapy.